Carregant...
EGFR-Targeted Therapies in the Post-Genomic Era
Over ninety percent of head and neck cancers overexpress the epidermal growth factor receptor (EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer prognosis and outcomes. Therapies targeting EGFR include monoclonal antibodies, tyrosine kinase inhibitors, phosphatidylin...
Guardat en:
| Publicat a: | Cancer Metastasis Rev |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693744/ https://ncbi.nlm.nih.gov/pubmed/28866730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10555-017-9687-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|